p53 is one of the most frequently mutated genes in human cancers (40% to 50% of GBMs have p53 mutations), and unlike most tumor suppressors, p53 is rarely deleted in GBM, since its alterations are mostly missense mutations in the DNA binding domain, leading to inhibition of its transcription factor activity [7, 8]. This evidence concerns the gene TP53 and cancer.